Alira Health Extends Global Market Access Capabilities Through Acquisition of Wellmera

Expanded market access expertise strengthens Alira Health’s suite of healthcare advisory services

 

News
Published on:
December 17, 2019

FRAMINGHAM, MA, USA – December 17, 2019 – Alira Health, a leading international healthcare and life sciences advisory firm, announced that it has acquired Wellmera, a healthcare consulting firm headquartered in Basel, Switzerland specializing in market access for the pharmaceutical and biotechnology industries. The acquisition will bring global expertise in market access, pricing and reimbursement, health economics, and real-world evidence to Alira Health’s suite of healthcare advisory services.

The collective organization will advance Alira Health’s mission of enabling healthcare transformation by supporting clients across their product and corporate life cycles, with services in product development, regulatory, clinical, strategic consulting, and transaction advisory. The Wellmera team brings a wealth of experience in helping clients develop evidence, devise pricing and market access approaches, and provide tailored strategies to local client affiliates in preparation for pricing and reimbursement negotiations around the world, with a focus on European markets.

We are thrilled to welcome Wellmera and their incredible team to Alira Health. This acquisition is an important step in achieving our vision of offering a full continuum of services, particularly in the critical areas of regulatory, clinical and market access,” said Gabriele Brambilla, CEO of Alira Health. “These expanded services will help us to deliver even greater value to our clients as they develop and bring to market the next generation of healthcare innovations.

The Wellmera team is excited to join Alira Health,” says Jean-François Ricci, PharmD PhD, President and Principal at Wellmera. “This partnership allows us to bring our market access expertise to a larger global organization, helping us to impact patient care on an even greater scale. We see many synergies with Alira Health’s lifecycle approach, and feel a strong connection in our passion for healthcare, our quality of work, and the culture of our teams.”

Jean-François Ricci will become Executive Vice President of Market Access and will lead Alira Health’s Market Access practice, covering pharma, biotech, and digital health in Europe and the United States.

About Wellmera:

Wellmera is a dynamic international consulting firm focused on market access, pricing and reimbursement, health economics, and real-world evidence. We help life sciences companies demonstrate value, optimize patient access, and realize the commercial opportunity for their products throughout the lifecycle.

Wellmera was established in 2011 in Basel, Switzerland and expanded in early 2018 to the US with offices in Cambridge, MA, and San Francisco, CA, leveraging synergies for global clients between Europe and the US.

To learn more about Alira Health's Market Access practice

Click here

Related news

Publications September 19, 2023
Opportunities and Challenges in the Therapeutic and CDMO Markets
Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth in this CHEManager article.
CDMO Pharma
News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
News August 31, 2023
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Life Sciences MedTech Pharma
Events August 10, 2023
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
EU Market Access
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Events July 31, 2023
ESMO Congress
We are excited to join the ESMO Congress in Madrid. to disseminate the latest cutting-edge data for oncologists and other stakeholders.
Drug Development Market Access Oncology Spain
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.